Member Info for bp82

https://www.novartis.com/news/media-releases/novartis-announces-planned-acquisition-endocyte-expand-expertise-radiopharmaceuticals-and-build-commitment-transformational-therapeutic-platforms

Hope we could match this with 201

They now need is a full blown CT III with hundred's of patients.

Whatever this was, early next year or first q, you have to sure before saying such thing.

And they can only say such thing when someone with deep pocket said YES and that yes can only be based on these results.

based on this someone has already committed to fund PHASE III, otherwise how can the BOD be so sure to start trial in first q of 2019.

They must have secured the funding.

of the company traded today.

What's BvsS?

the company has mentioned that they are very EXCITED with the results.

So there must be something that none of us understand.

what is the significance of todays news.

Dont they release all information through RNS which is in public domain.

Noooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooo.

Just hold on for a day or 2 I m getting more money baby. YOU ARE MINEEEEE ;)

they are getting contracts then it means the tech is working.

They why are they struggling to get more signed even to its not a very competitive area.

http://www.pharmatimes.com/magazine/2018/october_2018/ai_has_arrived

But if the deal happens than the SP is bound to go higher and that will result in smaller dilution and more confidence in company.

getting some money soon :))))))))

14:26 - 26/09
Buy 3000000 0.85p £25,350.00
14:27 - 26/09
Buy 3000000 0.85p £25,500.00
13:25 - 26/09
Sell 2474199 0.76p £18,700.00
08:17 - 26/09
Sell 822705 0.77p £6,293.69
08:11 - 26/09
Buy 822705 0.80p £6,561.07

janet walker
3rd degree connection3rd
Independent International Trade and Development Professional
London, United Kingdom

Promoting valirx on Linkdin. Also messaged Bill Gates :)

You mean £3.

Oh yes defo :)

Confirmation was received this week that Principal Investigators have approved and signed the Clinical Study Report and that the process of submission to and approval by the local ethics committees has commenced. Notification of receipt of the Clinical Study report was filed to the Ministry of Health in Tbilisi, before the end of July 2018 in accordance with regulatory expectations.



Commercial activity surrounding VAL401 has continued. Detailed discussions are in progress in respect to a pivotal Phase III Clinical Trial. Partners external to ValiRx and ValiSeek will have substantial input into the trial design, with first dosing anticipated next year.



VAL201

(VAL201 is currently in Phase I/II clinical trials for patients affected by hormone- sensitive and hormone-resistant prostate cancer.)

The VAL201 compound has demonstrated consistent high safety and tolerability, and signs of efficacy throughout its clinical study. A preliminary inspection of the clinical data derived from the original dosing regimen has been completed regarding all the subjects that have been treated to date. This inspection considered all dosing regimens. In summary, our preliminary observations highlight a dose-related impact on patients' physiology and chemistry, such as androgen PSA and various cell and protein turnover factors, which are important in the treatment of cancer. These are in line with anticipated outcomes as far as cancer reduction is concerned.

https://biopharmadealmakers.nature.com/users/33734-valiseek/posts/15197-reformulating-a-novel-therapeutic-for-lung-cancer

Will this hit £2. My Bentley is waiting for meeeeeeeeeeeeeeeeee :)

??

How long does it take them reply?

 Notification of receipt of the Clinical Study report was filed to the Ministry of Health in Tbilisi, before the end of July 2018 in accordance with regulatory expectations.